C. Elegans Genetic Strategies to Identify Novel Parkinson's Disease-associated Therapeutic Targets and Leads

Parkinson's Disease

Volumn , Issue , 2008, Pages 361-368

  Nass, Richard ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875021920     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374028-1.00027-0     Document Type: Chapter

References (37)

1. Artal-Sanz M., de Jong L., Tavernarakis N. Caenorhabditis elegans: A versatile platform for drug discovery. Biotechnol J 2006, 1405-1418.
2. Bargmann C.I. Neurobiology of the Caenorhabditis elegans genome. Science 1998, 282:2028-2033.
3. Braungart E., Gerlach M., Riederer P., Baumeister R., Hoener M.C. Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screening. Neurodegener Dis 2004, 1:175-183.
4. Model Organisms in Drug Discovery 2003, John Wiley and Sons, Holbroken, NY. P.M. Carroll, K. Fitzgerald (Eds.).
5. Faber P.W., Alter J.R., MacDonald M.E., Hard A.C. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci USA 1999, 101:6403-6408.
6. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
7. Guengerich F.P., MacDonald J.S. Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol 2007, 20:344-369.
8. Horrobin D.F. Realism in drug discovery - Cassandra be right?. Nat Biotechnol 2001, 19:1099-1100.
9. Kaletta T., Hengartner M.O. Finding function in novel targets: C. elegans as a model organism. Nat Rev Drug Discov 2006, 5:387-398.
10. Kaletta T., Butler L., Bogaert T. Caenorhabditis elegans: functional genomics in drug discovery: expanding paradigms. Model Organisms in Drug Discovery 2003, John Wiley and Sons. P.M. Carroll, K. Fitzgerald (Eds.).
11. Kamath R.S., Ahringer J. Genome-wide RNAi screening in Caenorhabditis elegans. Methods 2003, 30:313-321.
12. Kamath R.S., Fraser A.G., Dong Y., Poulin G., Durbin R., Gotta M., Kanapin A., Le Bot N., Moreno S., Sohrmann M., et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 2003, 421:231-237.
13. Lakso M., Vartianen S., Moilanen A.M., Sirvio J., Thomoas J.H., Nass R., Blakely R.D., Wong G. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α-synuclein. J Neurochem 2003, 86:165-172.
14. Liebler D.C., Guengerich F.P. Elucidating mechanisms of drug-induced toxicity. Nat Rev 2005, 4:410-420.
15. Link C.D. Transgenic invertebrates models of age-associated neurodegenerative diseases. Mech Ageing Dev 2001, 122:1639-1649.
16. Link E.M., Hardiman G., Sluder A.E., Johnson C.D., Liu L.X. Therapeutic target discovery using Caenorhabditis elegans. Pharmacogenomics 2000, 1:203-217.
17. McLaughlin B. Dopamine Neurotoxicity and Neurodegeneration 2001, Humana Press, Totowa, NJ, pp. 195-231.
18. Montgomery M.K., Xu S., Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci USA 1998, 95:15502-15507.
19. Nass R., Hahn M.K., Jessen T., McDonald P.W., Carvelli L., Blakely R.D. A genetic screen in Caenorhabditis elegans for dopamine neuron insensitivity to 6-hydroxydopamine identifies dopamine transporter mutants impacting transporter biosynthesis and trafficking. J Neurochem 2005, 94:774-785.
20. Nass R., Hall D.H., Miller D.M., Blakely R.D. Neurotoxin-induced degeneration of dopamine neurons in Caenorgabditis elegans. Proc Nat Acade Sci USA 2002, 99:3264-3269.
21. Nass R., Blakely R.B. The Caenorhabditis elegans dopaminergic system: Opportunities for insights into dopamine transport and neurodegeneration. Annu Rev Pharmacol Toxicol 2003, 43:521-544.
22. Nass R., Hamza I. The nematode C. elegans as a model to explore toxicology in vivo: solid and axenic growth culture conditions and compound exposure parameters. Curr Protocols Toxicol 2007, 15:1.9.1.1.9.18.
23. Nass R., Nichols S. Invertebrates as powerful genetic models for human neurodegenerative disease 2007, 567-588. John Wiley and Sons, Inc, Holboken, New Jersey. D.R. Sibley, I. Hanin, M. Kuhar, P. Skolnick (Eds.).
24. Nollen E.A., et al. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci USA 2004, 101:6403-6408.
25. Parkinson J. An Essay on the Shaking Palsy 1817, Whittingham and Rowland, London.
26. Rand, J.B., Johnson, C.D. (1995). Genetic pharmacology: Interactions between drugs and gene products in Caenorhabditis elegans. In Methods in Cell Biology, pp. 187-204. New York.
27. C. elegans II 1997, Cold Spring Harbor Laboratory Press, New York. D.L. Riddle, T. Blumenthal, B.J. Meyer, J.R. Priess (Eds.).
28. Sluder, A., and Baumeister, R. (2004). From genes to drugs: target validation in Caenorhabditis elegans. Drug Discovery Today: Technologies, Elsevier 171-177.
29. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997, 340:249-258.
30. Tatsumi M., Jansen K., Blakely R.D., Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999, 368:277-283.
31. Timmons L., Fire A. Specific interference by ingested dsRNA. Nature 1998, 395:854.
32. van Ham T.J., Thijssen K.L., Breitling R., Hofstra R.M.W., Plasterk R.H.A., Nollen E.A.A. C. elegans model identifies genetic modifiers of α-synuclein inclusion formation during aging. PLoS Genet 2008, 4(3):e10000027.
33. Vartiainen S., Pehkonen P., Lakso M., Nass R., Wong G. Identification of gene expression changes in transgenic C. elegans overexpressing human α-synuclein. Neurobio. Dis, 2006, 22:477-486.
34. Waldmeier P., Bozyczko-Coyne D., Williams M., Vaught J.L. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 2006, 72:1197-1206.
35. Westlund B., Stilwell G., Sluder A. Invertebrate disease models in neurotherapeutic discovery. Curr. Opin. Drug Discov, 2004, 7:169-178.
36. Wicks S.R., Yeh R.T., Gish W.R., Waterston R.H., Plasterk R.H. Rapid gene mapping in Caenorhabditis elegans using a high density polymorphism map. Nat Genet 2001, 28:160-164.
37. Zhang W., Wang T., Qin L., Gao H.M., Wilson B., Ali S.F., Zhang W., Hong J., Liu B. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J 2004, 18:589-591.